Supplemental Table 1 Treatment-related adverse events in this study and previous trials

Variables	PRODIGE4 /ACCORD11	FOLFIRINOX% (*n* = 86)	MPACT	Gem + nabPTX (*n* = 81)
Hematologic				
Grade ≥ 3 Anemia	7.8% (*n* = 13)	19.8% (*n*=17)	13% (*n*=53)	14.8% (*n*=12)
Grade ≥ 3 Thrombocytopenia	9.1% (*n* = 15)	8.1% (*n*=7)	13% (*n*=52)	6.2% (*n*=5)
Grade ≥ 3 Neutropenia	45.7% (*n* = 75)	74.4% (*n*=64)	38% (*n*=153)	46.9% (*n*=38)
Febrile neutropenia	5.4% (*n* = 9)	25.6% (*n*=22)	3% (*n*=14)	16.0% (*n*=13)
Nonhematologic				
Grade ≥ 3 Nausea/Vomiting	14.5% (*n* = 24)	41.9% (*n*=36)	NA	9.8% (*n*=8)
Grade ≥ 3 Diarrhea	12.7% (*n* = 21)	3.5% (*n*=3)	6% (*n*=24)	7.4% (*n*=6)
Grade ≥ 3 Fatigue	23.6% (*n* = 39)	20.9% (*n*=18)	17% (*n*=70)	28.4% (*n* = 23)
Grade ≥ 3 neuropathy	9.0% (*n* = 15)	3.5% (*n*=3)	17% (*n*=70)	18.5% (*n* = 15)